Department of Environmental Science, Baylor University, Waco, TX, USA.
Department of Biology, Baylor University, Waco, TX, USA.
Int J Nanomedicine. 2019 Jul 11;14:5159-5173. doi: 10.2147/IJN.S203330. eCollection 2019.
The use of liposomes as a drug delivery carrier (DDC) for the treatment of various diseases, especially cancer, is rapidly increasing, requiring more stringent synthesis, formulation, and preservation techniques to bolster safety and efficacy. Liposomes otherwise referred to as phospholipid vesicles are self-assembled colloidal particles. When formed in either the micrometer or nanometer size range, they are ideal candidates as DDC because of their biological availability, performance, activity, and compatibility. Defining and addressing the critical quality attributes (CQAs) along the pharmaceutical production scale will enable a higher level of quality control for reproducibility. More specifically, understanding the CQAs of nanoliposomes that dictate its homogeneity and stability has the potential to widen applications in biomedical science. To this end, we designed a study that aimed to define synthesis, characterization, formulation (encapsulation), preservation, and cargo delivery and trafficking as the major components within a target product profile for nanoliposomes. A series of synthetic schemes were employed to measure physicochemical properties relevant to nanomaterial drug product development, including concentration gradients, probe versus bath sonication, and storage temperature measured by microscopy (electron and light) and dynamic light scattering. Concentration was found to be a vital CQA as reducing concentrations resulted in nanometer-sized liposomes of <350 nm. Liposomes were loaded with microRNA and fluorescence spectroscopy was used to determine loading efficacy and stability over time. Lyophilization was used to create a dry powder formulation that was then assessed for stability for 6 months. Lastly, breast cancer cell lines were used to ensure efficacy of microRNA delivery and localization. We conclude that microRNA can be loaded into nanometer-sized liposomes, preserved for months in a dried form, and maintain encapsulation after extended time periods in storage.
脂质体作为一种药物递送载体(DDC)用于治疗各种疾病,特别是癌症,其应用正在迅速增加,这就需要更严格的合成、配方和保存技术来提高安全性和有效性。脂质体也称为磷脂囊泡,是自组装的胶体颗粒。当它们形成在微米或纳米尺寸范围内时,由于其生物利用度、性能、活性和相容性,它们是作为 DDC 的理想候选物。定义和解决药物生产规模的关键质量属性(CQAs)将能够实现更高水平的质量控制以确保重现性。更具体地说,了解决定纳米脂质体均匀性和稳定性的 CQAs 有可能拓宽其在生物医学科学中的应用。为此,我们设计了一项研究,旨在将合成、表征、配方(包封)、保存和货物输送及转运定义为纳米脂质体的目标产品特性概要中的主要组成部分。采用了一系列合成方案来测量与纳米材料药物产品开发相关的物理化学性质,包括浓度梯度、探针与浴式超声以及通过显微镜(电子和光)和动态光散射测量的储存温度。浓度被发现是一个至关重要的 CQA,因为降低浓度会导致小于 350nm 的纳米尺寸脂质体。将 miRNA 加载到脂质体中,并使用荧光光谱法来确定载药量和随时间的稳定性。冷冻干燥用于创建干粉配方,然后评估其 6 个月的稳定性。最后,使用乳腺癌细胞系来确保 miRNA 输送和定位的功效。我们得出结论,miRNA 可以被加载到纳米尺寸的脂质体中,可以在干燥形式下保存数月,并且在长时间储存后保持包封。